Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...

potentially pointing to potential for use in tandem with other weight-loss therapies, including Novo Nordisk's GLP-1 drug Wegovy (semaglutide). Brian Finan, head of obesity research at Novo ...